Table 2.

Clinical Remission in Adults

Study (year)	N	Outcome	Timepoint	Results
Panaccione 201921	2207	CR (CDAI<150)	26 weeks	<1 year: 57.8% (n=45) ≥1–<2 years: 35.8% (n=67) 2–≤5 years: 34.2% (n=196) >5 years: 33.7% (n=768) p=0.013
Ogata 2016†22	1693	CR (CDAI < 150)	24 weeks	<2 versus 2 to <5 years: OR 0.84 (0.26–2.65) p=0.76 <2 versus 5 to <10 years: OR 0.28 (0.10–0.80) p=0.02 <2 versus 10 to <20 years: OR 0.27 (0.10–0.75) p=0.01 <2 versus >20 years: OR 0.24 (0.08–0.71) p=0.01
Schreiber 201012	425	CR (CDAI ≤ 150)	26 weeks	<1 Year: 68.4% (n=19) ≥1 to <2 years: 55.0% (n=20) ≥2 to <5 years: 46.7% (n=45) ≥5 Years: 44.3% (n=131)
Faleck 201923	650	CR (complete resolution of all CD related symptoms) And CSFR (tapering off steroids completely, achieving clinical remission, and no repeat steroid prescription within 4 weeks of tapering)	26 weeks	CR ≤ 2 years vs >2 years: 38% vs 23% (p<0.05) CSFR ≤ 2 years vs >2 years: 43% vs 14% (p<0.05)
Schreiber 201311	777	CR (CDAI < 150)	26 weeks	<2 years: 46% (n=56) ≥2 to <5 years: 28% (n=95) ≥5 years: 32% (n=366)
			52 weeks	<2 years: 43% (n=56) ≥2 to <5 years: 30% (n=95) ≥5 years: 28% (n=366)
Reinisch 200920	945	CR (HBI ≤ 4)	20 weeks	<2 years: 58% (n=62/107) 2–5 years 56% (n=121/217) >5 years 50% (n=309/621)
Colombel 201517	188	CR (CDAI < 150) and Composite Outcomes	26 weeks	IFX+AZA Combination early versus non-early: CR: 81.5% vs 80.0% p<0.05 CR+MH: 63% vs 53.3% p<0.05 CR+CRPnorm: 76.5% vs 55.6% p>0.05 CR+MH+CRPnorm: 64.7% vs 44.4% p<0.05
D’Haens 200815	129	CSFR (CDAI < 150 and absence of corticosteroid treatment, and no intestinal resection)	26 weeks	Early combined immunosuppression group vs conventional management:  •60.6% (n=39/65) vs 35.9% (n=23/64)  •Δ=24.1% (95% CI 7.3–40.8, p=0.0062)
			52 weeks	Early combined immunosuppression group vs conventional management:  •61.5% (n=40/65) vs 42.2% (n=27/64)  •Δ=19.4% (95% CI 2.4–36.3, p=0.0278)

^†Study only reported odds ratios.